Adcock Ingram expects earnings to jump by half
The Bidvest-linked pharmaceuticals group appears to have turned a corner in 2017
Adcock Ingram expects headline earnings per share (HEPS) for the six months ended December 2016 to leap between 45% and 49%. Since early 2014, the Bidvest-linked pharmaceuticals group has been a somewhat bitter pill for shareholders to swallow. But it appears to have turned a corner in 2017, with the share price jumping from about R44 a share in late November to about R54 now. The group experienced a nonrecurring capital profit in the interim period resulting from the R407m disposal of part of its Indian business in 2016. This was tempered by certain nonrecurring accounting costs. Results for the six months are expected to be released on or around February 22.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.